Last reviewed · How we verify

Placebo (for Lidocaïne)

University of Liege · FDA-approved active Small molecule

A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.

A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes. Used for Control comparator in clinical trials evaluating Lidocaïne efficacy.

At a glance

Generic namePlacebo (for Lidocaïne)
Also known asNaCl 0.9%
SponsorUniversity of Liege
ModalitySmall molecule
Therapeutic areaClinical Trial Control
PhaseFDA-approved

Mechanism of action

Placebo is an inert substance used as a control in clinical trials to assess the efficacy of active drugs. Any observed effects result from patient expectation, the therapeutic context, and natural disease progression rather than direct molecular action. In this case, it serves as a comparator to evaluate the local anesthetic effects of Lidocaïne.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: